



## Varicella and Zoster Vaccination

Guest Editor:

### **Dr. Peter Maple**

1. Division of Clinical  
Neuroscience, Section of Clinical  
Neurology, University of  
Nottingham, Nottingham NG7  
2UH, UK

2. Department of Neurology,  
Nottingham University Hospitals  
NHS Trust, Nottingham NG7 2UH,  
UK

Deadline for manuscript  
submissions:

**31 January 2025**

### **Message from the Guest Editor**

In temperate climates such as the UK, many children have experienced varicella by the age of 10 years and by adulthood in excess of 90% of the population has evidence of prior VZV infection. In tropical zones, VZV infection tends to occur in individuals of older age groups. Effective vaccines are available to prevent varicella; however, uptake has been variable following concerns that varicella vaccination may result in increased cases of zoster later in life. Recently, zoster vaccines have also become available. In this Special Issue, varicella and zoster epidemiology will be addressed together with the benefits of vaccination, both in relation to differing geographical regions and in the face of new infectious challenges (SARS-CoV-2) and associations with neurological diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)